The Halland Osteoarthritis Cohort (HALLOA)

The Halland Osteoarthritis (HALLOA) Cohort Study - a Five-year Observational Longitudinal Study With Focus on Metabolic Osteoarthritis

Osteoarthritis is the most common musculoskeletal disease and is characterized by cartilage destruction, osteophyte formation, subchondral bone sclerosis and cysts. Modern treatment strategies, as well as preventive measures, include early detection and knowledge of the early course of the disease. This includes how stress patterns, physical activity, impaired function and metabolic changes and other comorbidities affect development and possible associations with osteoarthritis.

The overall objective was to study the early development of osteoarthritis of the knee and its association with hand- and general osteoarthritis, metabolic diseases, biomarkers, long-term pain, physical function and stress patterns

Study Overview

• Status: Active, not recruiting
• Conditions: Osteoarthritis, Knee; Osteoarthritis Hand; Osteoarthritis Generalized

Detailed Description

The overall objective was to study the early development of osteoarthritis of the knee and its association with hand- and general osteoarthritis, metabolic diseases, biomarkers, long-term pain, physical function and stress patterns.

The project includes 4 different research areas that are studied with the help of several smaller sub-studies:

Research area 1: Metabolic osteoarthritis - to study the connections between metabolic factors and osteoarthritis development in the knee and hand.

A. Relationship between knee osteoarthritis and metabolic factors B. Relationship between osteoarthritis of the hand and metabolic factors Research area 2: Biomarkers in knee and hand osteoarthritis - to study cartilage and bone markers that reflect different processes in osteoarthritis development, e.g. inflammation, matrix degradation both in the short and long term Research area 3: Pain and osteoarthritis - to study pain development and pain pressure thresholds in relation to lifestyle, depression and health-related quality of life in individuals with symptomatic knee osteoarthritis Research area 4: Physical function and osteoarthritis - to study physical function, physical activity and measured stress patterns, as well as changes in stress patterns and the relationship between these and the development of osteoarthritis over time.

Study design This is a longitudinal cohort study including 306 individuals with knee pain in the southwest of Sweden, the Halland osteoarthritis (HALLOA) cohort. The enrolments took place from 2017-2019. The participants were recruited: 1) by primary health care clinics when searching care for knee pain, or 2) by advertisements in local newspapers. The inclusion criterions were current knee pain, aged 30-65 years, with no former known radiographic knee osteoarthritis (RKOA). the exclusion criterions were no cruciate ligament rupture or rheumatologic disorder. A general practitioner examined all participants to confirm the exclusion criteria.

The cohort will be followed for five years with yearly follow-ups.

• Study Type: Observational
• Enrollment (Actual): 312

Contacts and Locations

Study Locations

• Sweden
  • Halmstad, Sweden, SE-30274
    • Spenshult Research and Development center (FoU Spenshult)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 30 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

306 individuals with knee pain without cruciate ligament injury, age between 30 and 65 years

Description

Inclusion Criteria:

Knee pain

Exclusion Criteria:

Cruciate ligament injury and rheumatic disease (RA, PsoA, As, Sponylarthritis etc)

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
HALLOA; 306 individuals with knee pain in the age between 30 and 65 years, without cruciate ligament injury

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
BMI (kg/m2)	weight (kg) and height (m) are meassured and BMI will be calculated	At baseline
BMI (kg/m2)	weight (kg) and height (m) are meassured and BMI will be calculated	At 2 years follow-up
BMI (kg/m2)	weight (kg) and height (m) are meassured and BMI will be calculated	At 5 years follow-up
Abdominal circumference (cm)	Abdominal circumference are meassured with measuring tape at navel height	At baseline
Abdominal circumference (cm)	Abdominal circumference are meassured with measuring tape at navel height	At 2 years follow-up
Abdominal circumference (cm)	Abdominal circumference are meassured with measuring tape at navel height	At 5 years follow-up
Body composition	Body composition are assessed by Inbody 770, which gives data on proportion of muscle and body fat (separate meassures on visceral fat	At baseline
Body composition	Body composition are assessed by Inbody 770, which gives data on proportion of muscle and body fat (separate meassures on visceral fat	At 2 years follow-up
Body composition	Body composition are assessed by Inbody 770, which gives data on proportion of muscle and body fat (separate meassures on visceral fat	At 5 years follow-up
Glucos	Fasting glucos (mmol/L) meassured in serum	At Baseline
Glucos	Fasting glucos (mmol/L) meassured in serum	At 1 year follow-up
Glucos	Fasting glucos (mmol/L) meassured in serum	At 2 years follow-up
Glucos	Fasting glucos (mmol/L) meassured in serum	At 3 years follow-up
Glucos	Fasting glucos (mmol/L) meassured in serum	At 4 years follow-up
Glucos	Fasting glucos (mmol/L) meassured in serum	At 5 years follow-up
HbA1c	HbA1c (mmol/mol) meassured in serum	At baseline
HbA1c	HbA1c (mmol/mol) meassured in serum	At 1 year follow-up
HbA1c	HbA1c (mmol/mol) meassured in serum	At 2 years follow-up
HbA1c	HbA1c (mmol/mol) meassured in serum	At 3 years follow-up
HbA1c	HbA1c (mmol/mol) meassured in serum	At 4 years follow-up
HbA1c	HbA1c (mmol/mol) meassured in serum	At 5 years follow-up
Total-cholesterol	Total-cholesterol (mmol/L) meassured in serum	At baseline
Total-cholesterol	Total-cholesterol (mmol/L) meassured in serum	At 1 year follow-up
Total-cholesterol	Total-cholesterol (mmol/L) meassured in serum	At 2 years follow-up
Total-cholesterol	Total-cholesterol (mmol/L) meassured in serum	At 3 years follow-up
Total-cholesterol	Total-cholesterol (mmol/L) meassured in serum	At 4 years follow-up
Total-cholesterol	Total-cholesterol (mmol/L) meassured in serum	At 5 years follow-up
Triglycerides	Triglycerides (mmol/L) meassured in serum	At baseline
Triglycerides	Triglycerides (mmol/L) meassured in serum	At 1 year follow-up
Triglycerides	Triglycerides (mmol/L) meassured in serum	At 2 years follow-up
Triglycerides	Triglycerides (mmol/L) meassured in serum	At 3 years follow-up
Triglycerides	Triglycerides (mmol/L) meassured in serum	At 4 years follow-up
Triglycerides	Triglycerides (mmol/L) meassured in serum	At 5 years follow-up
LDL-cholesterol	LDL-cholesterol (mmol/L) meassured in serum	At baseline
LDL-cholesterol	LDL-cholesterol (mmol/L) meassured in serum	At 1 year follow-up
LDL-cholesterol	LDL-cholesterol (mmol/L) meassured in serum	At 2 years follow-up
LDL-cholesterol	LDL-cholesterol (mmol/L) meassured in serum	At 3 years follow-up
LDL-cholesterol	LDL-cholesterol (mmol/L) meassured in serum	At 4 years follow-up
LDL-cholesterol	LDL-cholesterol (mmol/L) meassured in serum	At 5 years follow-up
HDL-cholesterol	HDL-cholesterol (mmol/L) meassured in serum	At baseline
HDL-cholesterol	HDL-cholesterol (mmol/L) meassured in serum	At 1 year follow-up
HDL-cholesterol	HDL-cholesterol (mmol/L) meassured in serum	At 2 years follow-up
HDL-cholesterol	HDL-cholesterol (mmol/L) meassured in serum	At 3 years follow-up
HDL-cholesterol	HDL-cholesterol (mmol/L) meassured in serum	At 4 years follow-up
HDL-cholesterol	HDL-cholesterol (mmol/L) meassured in serum	At 5 years follow-up
Sensitive C-Reactive Protein (CRP)	sensitive CRP (g/L) meassured in serum	At baseline
Sensitive C-Reactive Protein (CRP)	sensitive CRP (g/L) meassured in serum	At 1 year follow-up
Sensitive C-Reactive Protein (CRP)	sensitive CRP (g/L) meassured in serum	At 2 years follow-up
Sensitive C-Reactive Protein (CRP)	sensitive CRP (g/L) meassured in serum	At 3 years follow-up
Sensitive C-Reactive Protein (CRP)	sensitive CRP (g/L) meassured in serum	At 4 years follow-up
Sensitive C-Reactive Protein (CRP)	sensitive CRP (g/L) meassured in serum	At 5 years follow-up
Interleukin-1 (IL-1)	IL-1 (pg/mL) meassured in plasma with ELISA	At baseline
Interleukin-1 (IL-1)	IL-1 (pg/mL) meassured in plasma with ELISA	At 1 year follow-up
Interleukin-1 (IL-1)	IL-1 (pg/mL) meassured in plasma with ELISA	At 2 years follow-up
Interleukin-1 (IL-1)	IL-1 (pg/mL) meassured in plasma with ELISA	At 3 years follow-up
Interleukin-1 (IL-1)	IL-1 (pg/mL) meassured in plasma with ELISA	At 4 years follow-up
Interleukin-1 (IL-1)	IL-1 (pg/mL) meassured in plasma with ELISA	At 5 years follow-up
Interleukin-6 (IL-6)	IL-6 (pg/mL) meassured in plasma with ELISA	At baseline
Interleukin-6 (IL-6)	IL-6 (pg/mL) meassured in plasma with ELISA	At 1 year follow-up
Interleukin-6 (IL-6)	IL-6 (pg/mL) meassured in plasma with ELISA	At 2 years follow-up
Interleukin-6 (IL-6)	IL-6 (pg/mL) meassured in plasma with ELISA	At 3 years follow-up
Interleukin-6 (IL-6)	IL-6 (pg/mL) meassured in plasma with ELISA	At 4 years follow-up
Interleukin-6 (IL-6)	IL-6 (pg/mL) meassured in plasma with ELISA	At 5 years follow-up
Tumor Necrosis Factor-alfa (TNF-alfa)	TNF-alfa (pg/mL) meassured in plasma with ELISA	At baseline
Tumor Necrosis Factor-alfa (TNF-alfa)	TNF-alfa (pg/mL) meassured in plasma with ELISA	At 1 year follow-up
Tumor Necrosis Factor-alfa (TNF-alfa)	TNF-alfa (pg/mL) meassured in plasma with ELISA	At 2 years follow-up
Tumor Necrosis Factor-alfa (TNF-alfa)	TNF-alfa (pg/mL) meassured in plasma with ELISA	At 3 years folllow-up
Tumor Necrosis Factor-alfa (TNF-alfa)	TNF-alfa (pg/mL) meassured in plasma with ELISA	At 4 years follow-up
Tumor Necrosis Factor-alfa (TNF-alfa)	TNF-alfa (pg/mL) meassured in plasma with ELISA	At 5 years follow-up
Leptin	Leptin (ng/mL) meassured in serum with ELISA	At baseline
Leptin	Leptin (ng/mL) meassured in serum with ELISA	At 1 year follow-up
Leptin	Leptin (ng/mL) meassured in serum with ELISA	At 2 years follow-up
Leptin	Leptin (ng/mL) meassured in serum with ELISA	At 3 years follow-up
Leptin	Leptin (ng/mL) meassured in serum with ELISA	At 4 years follow-up
Leptin	Leptin (ng/mL) meassured in serum with ELISA	At 5 years follow-up
Galectin-1	Galectin-1 (ng/mL) meassured in plasma with ELISA	At baseline
Galectin-1	Galectin-1 (ng/mL) meassured in plasma with ELISA	At 1 year follow-up
Galectin-1	Galectin-1 (ng/mL) meassured in plasma with ELISA	At 2 years follow-up
Galectin-1	Galectin-1 (ng/mL) meassured in plasma with ELISA	At 3 years follow-up
Galectin-1	Galectin-1 (ng/mL) meassured in plasma with ELISA	At 4 years follow-up
Galectin-1	Galectin-1 (ng/mL) meassured in plasma with ELISA	At 5 years follow-up
One-leg rise	Knee strenght are assessed by one-leg rise	At baseline
One-leg rise	Knee strenght are assessed by one-leg rise	At 2 years follow-up
One-leg rise	Knee strenght are assessed by one-leg rise	At 5 years follow-up
30s-chair stand test	Knee strenght are assessed by 30s-chair stand test	At baseline
30s-chair stand test	Knee strenght are assessed by 30s-chair stand test	At 2 years follow-up
30s-chair stand test	Knee strenght are assessed by 30s-chair stand test	At 5 years follow-up
Maximal voluntary isometric contraction of Quadriceps	Maximal voluntary isometric contraction of Quadriceps assessed by dynamometer (N)	At baseline
Maximal voluntary isometric contraction of Quadriceps	Maximal voluntary isometric contraction of Quadriceps assessed by dynamometer (N)	At 2 years follow-up
Maximal voluntary isometric contraction of Quadriceps	Maximal voluntary isometric contraction of Quadriceps assessed by dynamometer (N)	At 5 years follow-up
Hand strenght	Hand strenght are assessed by grippit (N)	At baseline
Hand strenght	Hand strenght are assessed by grippit (N)	At 2 years follow-up
Hand strenght	Hand strenght are assessed by grippit (N)	At 5 years follow-up
Fitness	Fitness are assessed by Åstrands test	At 2 years follow-up
Fitness	Fitness are assessed by Åstrands test	At 5 years follow-up
Pain thresholds	pain threshold are assesed by computerized pressure algometry on eight predefined tender points out of the 18 points as part of the definition of fibromyalgia	At baseline
Pain thresholds	pain threshold are assesed by computerized pressure algometry on eight predefined tender points out of the 18 points as part of the definition of fibromyalgia	At 2 years follow-up
Pain thresholds	pain threshold are assesed by computerized pressure algometry on eight predefined tender points out of the 18 points as part of the definition of fibromyalgia	At 5 years follow-up
Knee injury and osteoarthritis outcome score (KOOS)	KOOS consists of 5 subscales, assessing self reported knee pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL).	At baseline
Knee injury and osteoarthritis outcome score (KOOS)	KOOS consists of 5 subscales, assessing knee pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL).	At 1 year follow-up
Knee injury and osteoarthritis outcome score (KOOS)	KOOS consists of 5 subscales, assessing knee pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL).	At 2 years follow-up
Knee injury and osteoarthritis outcome score (KOOS)	KOOS consists of 5 subscales, assessing knee pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL).	At 3 years follow-up
Knee injury and osteoarthritis outcome score (KOOS)	KOOS consists of 5 subscales, assessing knee pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL).	At 4 years follow-up
Knee injury and osteoarthritis outcome score (KOOS)	KOOS consists of 5 subscales, assessing knee pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL).	At 5 years follow-up
Pain mannequin	Patient reported pain distribution	At baseline
Pain mannequin	Patient reported pain distribution	At 1 year follow-up
Pain mannequin	Patient reported pain distribution	At 2 years follow-up
Pain mannequin	Patient reported pain distribution	At 3 years follow-up
Pain mannequin	Patient reported pain distribution	At 4 years follow-up
Pain mannequin	Patient reported pain distribution	At 5 years follow-up
Pain intensity	Patient reported pain intensity by NRS scale 0-10 (best to worst)	At baseline
Pain intensity	Patient reported pain intensity by NRS scale 0-10 (best to worst)	At 1 year follow-up
Pain intensity	Patient reported pain intensity by NRS scale 0-10 (best to worst)	At 2 years follow-up
Pain intensity	Patient reported pain intensity by NRS scale 0-10 (best to worst)	At 3 years follow-up
Pain intensity	Patient reported pain intensity by NRS scale 0-10 (best to worst)	At 4 years follow-up
Patient intensity	Patient reported pain intensity by NRS scale 0-10 (best to worst)	At 5 years follow-up
Radiographic assessment of the knees	radiographic assessment of tibiofemoral- and patellofemoral joint in the knee	At baseline
Radiographic assessment of the knees	radiographic assessment of tibiofemoral- and patellofemoral joint in the knee	At 1 year follow-up
Radiographic assessment of the knees	radiographic assessment of tibiofemoral- and patellofemoral joint in the knee	At 2 years follow-up
Radiographic assessment of the knees	radiographic assessment of tibiofemoral- and patellofemoral joint in the knee	At 3 years follow-up
Radiographic assessment of the knees	radiographic assessment of tibiofemoral- and patellofemoral joint in the knee	At 4 years follow-up
Radiographic assessment of the knees	radiographic assessment of tibiofemoral- and patellofemoral joint in the knee	At 5 years follow-up
Radiographic assessment of the hands	Radiographic assessment of the hands.	At 2 years follow-up
Radiographic assessment of the hands	Radiographic assessment of the hands.	At 5 years follow-up
Mechanical load	Movement behavior measured with a triaxle accelerometer at work and leisure over 7 days	At inclusion
Mechanical load	Movement behavior measured with a triaxle accelerometer at work and leisure over 7 days	At 2 years follow-up
Mechanical load	Movement behavior measured with a triaxle accelerometer at work and leisure over 7 days	At 5 years follow-up

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Blood samples for biobanking	serum and plasma for biobanking in -70 degrees celcius	At baseline
Blood samples for biobanking	serum and plasma for biobanking in -70 degrees celcius	At 1 year follow-up
Blood samples for biobanking	serum and plasma for biobanking in -70 degrees celcius	At 2 years follow-up
Blood samples for biobanking	serum and plasma for biobanking in -70 degrees celcius	At 3 years follow-up
Blood samples for biobanking	serum and plasma for biobanking in -70 degrees celcius	At 4 years follow-up
Blood samples for biobanking	serum and plasma for biobanking in -70 degrees celcius	At 5 years follow-up
Patient reported physical activity	Patient reported physical activity with questions duration and intensity according to WHO recommendations	At baseline
Patient reported physical activity	Patient reported physical activity with questions duration and intensity according to WHO recommendations	At 1 year follow-up
Patient reported physical activity	Patient reported physical activity with questions duration and intensity according to WHO recommendations	At 2 years follow-up
Patient reported physical activity	Patient reported physical activity with questions duration and intensity according to WHO recommendations	At 3 years follow-up
Patient reported physical activity	Patient reported physical activity with questions duration and intensity according to WHO recommendations	At 4 years follow-up
Patient reported physical activity	Patient reported physical activity with questions duration and intensity according to WHO recommendations	At 5 years follow-up
Patient reported smoking and snuff habits	Patient reported smoking habits, year for smoke or snuff cessation, number of cigarettes or amount of snuff	At baseline
Patient reported smoking and snuff habits	Patient reported smoking habits, year for smoke or snuff cessation, number of cigarettes or amount of snuff	At 1 years follow-up
Patient reported smoking and snuff habits	Patient reported smoking habits, year for smoke or snuff cessation, number of cigarettes or amount of snuff	At 2 years follow-up
Patient reported smoking and snuff habits	Patient reported smoking habits, year for smoke or snuff cessation, number of cigarettes or amount of snuff	At 3 years follow-up
Patient reported smoking and snuff habits	Patient reported smoking habits, year for smoke or snuff cessation, number of cigarettes or amount of snuff	At 4 years follow-up
Patient reported smoking and snuff habits	Patient reported smoking habits, year for smoke or snuff cessation, number of cigarettes or amount of snuff	At 5 years follow-up
Patient reported diets	Patient reported diets and intake of fruits and sweets	At baseline
Patient reported diets	Patient reported diets and intake of fruits and sweets	At 1 year follow-up
Patient reported diets	Patient reported diets and intake of fruits and sweets	At 2 years follow-up
Patient reported diets	Patient reported diets and intake of fruits and sweets	At 3 years follow-up
Patient reported diets	Patient reported diets and intake of fruits and sweets	At 4 years follow-up
Patient reported diets	Patient reported diets and intake of fruits and sweets	At 5 years follow-up
Patient reported alcohol habits	Patient reported alcohol habis assessed by AUDIT C	At baseline
Patient reported alcohol habits	Patient reported alcohol habis assessed by AUDIT C	At 1 year follow-up
Patient reported alcohol habits	Patient reported alcohol habis assessed by AUDIT C	At 2 years follow-up
Patient reported alcohol habits	Patient reported alcohol habis assessed by AUDIT C	At 3 years follow-up
Patient reported alcohol habits	Patient reported alcohol habis assessed by AUDIT C	At 4 years follow-up
Patient reported alcohol habits	Patient reported alcohol habis assessed by AUDIT C	At 5 years follow-up
Hospital Anxiety and Depression Scale (HADS)	HADS is a simple self-assessment form that shows a measure of the patient's mood.	At baseline
Hospital Anxiety and Depression Scale (HADS)	HADS is a simple self-assessment form that shows a measure of the patient's mood.	At 1 year follow-up
Hospital Anxiety and Depression Scale (HADS)	HADS is a simple self-assessment form that shows a measure of the patient's mood.	At 2 years follow-up
Hospital Anxiety and Depression Scale (HADS)	HADS is a simple self-assessment form that shows a measure of the patient's mood.	At 3 years follow-up
Hospital Anxiety and Depression Scale (HADS)	HADS is a simple self-assessment form that shows a measure of the patient's mood.	At 4 years follow-up
Hospital Anxiety and Depression Scale (HADS)	HADS is a simple self-assessment form that shows a measure of the patient's mood.	At 5 years follow-up
Health literacy	Health literacy assessed with the Swedish Functional Health Literacy scale	At 2 years follow-up
Health literacy	Health literacy assessed with the Swedish Functional Health Literacy scale	At 3 years follow-up
Health literacy	Health literacy assessed with the Swedish Functional Health Literacy scale	At 5 years follow-up
Clinical examination of the knees	Clinical examination to assessing clinical knee OA	At baseline
Clinical examination of the knees	Clinical examination to assessing clinical knee OA	At 2 years follow-up
Clinical examination of the knees	Clinical examination to assessing clinical knee OA	At 5 years follow-up
Clinical examination of the hands	Clinical examination of the hands assessing clinical hand OA	At baseline
Clinical examination of the hands	Clinical examination of the hands assessing clinical hand OA	At 2 years follow-up
Clinical examination of the hands	Clinical examination of the hands assessing clinical hand OA	At 5 years follow-up
Blood pressure	Blood pressure assessed in sitting position after rest, mmHg	At baseline
Blood pressure	Blood pressure assessed in sitting position after rest, mmHg	At 2 years follow-up
Blood pressure	Blood pressure assessed in sitting position after rest, mmHg	At 5 years follow-up

Collaborators and Investigators

• Sponsor: FoU Center Spenshult
• Collaborators: The Swedish Rheumatism Ass
• Investigators: Principal Investigator: Maria LE Andersson, ass.prof., FoU Spenshult

Publications and helpful links

General Publications

• Andersson M, Haglund E, Aili K, Bremander A, Bergman S. Associations between metabolic factors and radiographic knee osteoarthritis in early disease - a cross-sectional study of individuals with knee pain. BMC Musculoskelet Disord. 2022 Oct 28;23(1):938. doi: 10.1186/s12891-022-05881-x.
• Andersson MLE, Haglund E, Aili K, Bremander A, Bergman S. Cohort profile: the Halland osteoarthritis (HALLOA) cohort-from knee pain to osteoarthritis: a longitudinal observational study in Sweden. BMJ Open. 2022 Jul 14;12(7):e057086. doi: 10.1136/bmjopen-2021-057086.

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2016
• Primary Completion (Actual): October 1, 2019
• Study Completion (Anticipated): October 1, 2024

Study Registration Dates

• First Submitted: February 2, 2021
• First Submitted That Met QC Criteria: June 9, 2021
• First Posted (Actual): June 16, 2021

Study Record Updates

• Last Update Posted (Actual): June 16, 2021
• Last Update Submitted That Met QC Criteria: June 9, 2021
• Last Verified: May 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Osteoarthritis; Osteoarthritis, Knee
• Other Study ID Numbers: HALLOA

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No